Given that the interpretation on the results of meta-analyses was complicated by interstudy heterogeneity, Wu et al. recently reported the data from a 24-year prospective cohort study (n = 47,885), which suggests that higher intake of ALA is not associated with the lethal prostate cancer risk after the introduction of PSA screening (Wu et al., 2018). This evidence concerns the gene KLK3 and prostate carcinoma.